Implementation and Patient Outcomes of a Pediatric COVID-19 Monoclonal Antibody ProgramArticle Published on 2022-12-282023-07-10 Journal: Journal of the Pediatric Infectious Diseases Socie [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 pediatric SARS-CoV-2 neutralizing antibody Sotrovimab. [DOI] 10.1093/jpids/piac107 PMC 바로가기
Uncovering hidden sources of SARS-CoV-2 viral evolution: A call to actionEditorial Published on 2022-12-012023-07-10 Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), [키워드] bamlanivimab immunosuppression. SARS-CoV-2 evolution [DOI] 10.1111/tid.13910 PMC 바로가기 [Article Type] Editorial
Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation ElectrophoresisArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] 진단, [키워드] added antibody assay interference B-cell bamlanivimab Casirivimab Cell characterization COVID-19 diagnostic Electrophoresis etesevimab evaluate evaluated Imdevimab Immunofixation immunofixation electrophoresis in vitro infused Interference medication monoclonal monoclonal antibody monoclonal antibody therapy neoplasm Patient patients plasma platform producing recognizing serum Serum protein serum protein electrophoresis. serum sample serum samples Sotrovimab sustained tested therapeutic [DOI] 10.1093/jalm/jfac064 PMC 바로가기
Bamlanivimab Use in a Military Treatment FacilityArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Administered administration Admission analyzed approval approved Arm bamlanivimab Care caused cohort study coronavirus coronavirus disease COVID-19 COVID-19 patient death declined diagnosed Disease progression facility FDA Follow-up Guidance help hospital Hospital admission Hospitalization information initial inpatient admission institutional review board intravenous IRB lack Mild-to-moderate monoclonal antibody Patient patients patients with SARS-CoV-2 placebo group Prevent Primary outcome progression provided receiving replicated reported required retrospective risk risk factor SARS-CoV-2 secondary outcome self-reported symptom severe COVID-19 small sample size Spread statistical significance statistically significant Study design Symptom treated Treatment treatment group virus-neutralizing was obtained were given Wuhan, China [DOI] 10.1093/milmed/usab188 PMC 바로가기
The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral ImmunityArticle Published on 2022-09-262022-11-15 Journal: International Journal of Molecular Sciences [Category] SARS, 변종, 진단, [키워드] ACE2 ACE2 binding amino acid changes antibody bamlanivimab Better bind binding BNT162b2 BNT162b2 mRNA BNT162b2 vaccine chance COVID-19 Delta delta variant dropped evaluate the effect human Angiotensin-converting enzyme immunized individual L452R Lambda less Ligand mRNA Mutation mutations Protective protective effect RBD Receptor binding domain SARS-CoV-2 sera serum antibody serum antibody. T478K the RBD titer vaccinated individual vaccination Vaccine variant variants of concern variants of interest VoC WHO wild type World Health Organization [DOI] 10.3390/ijms231911325 PMC 바로가기
SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbiditiesArticle Published on 2022-09-012022-11-15 Journal: Journal of clinical pharmacy and therapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] 30-Day mortality BAM bamlanivimab black changed clinical trials Cohort cohort of patient Combination Comorbidity comparable coronavirus disease COVID-19 etesevimab etesevimab. evaluated groups high-risk patient Hospitalization incidence laboratory-confirmed LOS male median age Median BMI monoclonal antibody monotherapy Neutralizing outcome outcomes Outpatient Patient provided receiving recent reduced Result retrospective cohort study SARS-CoV-2 SARS-CoV-2 neutralizing antibody secondary shown significantly symptom onset treated [DOI] 10.1111/jcpt.13694 PMC 바로가기
Evolution of Anti-SARS-CoV-2 Therapeutic AntibodiesArticle Published on 2022-08-282022-11-15 Journal: International Journal of Molecular Sciences [Category] SARS, 변종, 진단, [키워드] antibodies antibody approval authorization bamlanivimab bebtelovimab Casirivimab caused Characteristics cilgavimab claimed conserved COVID-19 COVID-19 pandemic Critical Diseases drug Efficacy EMA Emergency epitope etesevimab EUA European Evolution of SARS-CoV-2 FDA Features food HCDR3 help Imdevimab information Interaction Medicine Modification neutralization nine Prevent RBD regdanvimab regions residue SARS-CoV-2 somatic mutations Sotrovimab the receptor-binding domain therapeutic therapeutic antibodies Tixagevimab treat variants of concern variants of concern. viral infection VoC VOCs [DOI] 10.3390/ijms23179763 PMC 바로가기
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19COVID-19로 입원하지 않은 성인을 대상으로 한 무작위 시험에서 밤라니비맙의 항바이러스 및 임상 활성Randomized Controlled Trial Published on 2022-08-222022-09-11 Journal: Nature Communications [Category] SARS, 바이오마커, 변종, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] 1:1 adverse events Antiviral bamlanivimab clinical activity Clinical efficacy COVID-19 symptom COVID-19 symptoms COVID-19 therapeutics evaluated Evidence evidence of faster Inflammatory marker inflammatory markers median modeling monoclonal antibodies monoclonal antibody nasopharyngeal nasopharyngeal viral no differences Placebo Primary outcomes proportion provide Randomized Randomized controlled trial randomized trial reductions in risk risk ratio Safety SARS-CoV-2 RNA Symptom symptom duration undetectable variants of SARS-CoV-2 Viral with COVID-19 [DOI] 10.1038/s41467-022-32551-2 PMC 바로가기 [Article Type] Randomized Controlled Trial
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection단일 클론 항체 치료는 SARS-CoV-2 감염에서 빠른 배양 전환을 유도합니다Clinical Trial Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antibody treatment bamlanivimab benefit clearance collected coronavirus Coronavirus 2019 COVID COVID therapies COVID-19 Culture mAb mAbs monoclonal monoclonal antibodies monoclonal antibody nasal swab offer onward transmission participant performed Placebo qPCR raise receiving recrudescence reducing resistance respiratory SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 subset Transmission Treatment Trial Viral viral culture viral culture. Viral load Viral RNA virus while [DOI] 10.1016/j.xcrm.2022.100678 PMC 바로가기 [Article Type] Clinical Trial